Summary of the Conference Call for Borui Pharmaceutical Company Overview - **Company**: Borui Pharmaceutical - **Key Collaborations**: Huazhu Sanjiu, Hanyu Pharmaceutical Industry Insights - **Market Potential**: The GLP-1 market is projected to reach a scale of $100 billion by 2030, indicating significant growth opportunities for leading companies in this sector [6][12]. Key Points and Arguments Strategic Collaborations - **Collaboration with Huazhu Sanjiu**: - A commercial partnership was established to leverage Huazhu's strong market access and promotional capabilities in hospitals and retail [2][3]. - Huazhu Sanjiu paid CNY 282 million (approximately $40 million) as a milestone fee for product distribution rights, reflecting high sales expectations for Borui's products [2][9]. - This partnership aims to address channel issues post-product launch and enhance market penetration [5][7]. - **Collaboration with Hanyu Pharmaceutical**: - A strategic agreement was signed to ensure stable supply chains and meet future commercialization demands [4][16]. - Hanyu has multiple peptide products approved in the U.S., which strengthens Borui's quality assurance and regulatory compliance [4][16]. Product Development and Pipeline - **GLP-1 Pipeline**: - Borui's GLP-1 pipeline is robust, with strong collaborations enhancing R&D capabilities and commercial readiness [2][6]. - The Amlin pipeline shows promise in diabetes and weight loss, with milder gastrointestinal side effects and minimal impact on heart rate [2][14]. - **Amlin Drug Efficacy**: - Amlin has demonstrated significant additive effects at high doses, achieving over 30% weight loss, comparable to surgical outcomes [2][15]. - The drug's unique characteristics may address limitations of existing weight loss medications [14][15]. Market Expansion Plans - **Global Market Strategy**: - Borui plans to actively expand into overseas markets, maintaining global rights for its products despite domestic partnerships [10][11]. - Ongoing clinical trials in the U.S. for the 0,504 injection are progressing, with plans for further phases [13][11]. Competitive Landscape - **Positioning Against Competitors**: - Borui aims to establish itself as a leader in the GLP-1 segment through strategic partnerships and innovative product offerings [6][12]. - The collaboration with Huazhu Sanjiu and Hanyu Pharmaceutical is expected to enhance Borui's competitive edge in both domestic and international markets [5][16]. Additional Important Insights - **Regulatory Considerations**: - The partnerships are designed to bolster Borui's regulatory capabilities and address potential supply chain concerns from future partners [16]. - **Market Dynamics**: - The collaboration with Huazhu Sanjiu is seen as a strategic move to accelerate the transition from clinical development to commercialization in China [16]. This summary encapsulates the critical insights from the conference call, highlighting Borui Pharmaceutical's strategic initiatives, product pipeline, and market expansion plans.

Group 1 - The core viewpoint highlights the strong performance of the innovative drug ETF (560900), which rose over 1% on August 5, 2025, with significant trading volume and notable increases in constituent stocks [1] - The innovative drug ETF (560900) experienced a weekly scale growth of 219.80 million yuan, ranking first among comparable funds, and a substantial increase of 4 million shares [1] - Recent net inflows into the innovative drug ETF (560900) totaled 973,700 yuan, with a total of 11.04 million yuan in net inflows over the past five trading days [1] Group 2 - Century Securities noted a resurgence in innovative drug licensing collaborations, including a significant $500 million upfront payment deal between Hengrui Medicine and GlaxoSmithKline, covering a potential total of $12 billion [2] - The innovative drug asset landscape is diversifying beyond oncology to include respiratory, metabolic, and immune therapies, with collaborations involving multinational corporations, new companies, state-owned enterprises, and biotech firms [2] - The innovative drug ETF (560900) closely tracks the CSI Innovative Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug research and development [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to assist investors in identifying quality technology companies globally, capitalizing on the new wave of technological advancements driven by AI [3]

Group 1: Government Bonds and Futures - The new tax policy on government bond interest income, effective from August 8, 2025, will significantly impact the cash bond market and the pricing logic of government bond futures [1][2] - The potential for CTD (cheapest to deliver) bond switching exists, particularly for T and TS contracts, which may create cross-period arbitrage opportunities [2][3] - The likelihood of a "short squeeze" in government bond futures is higher if new bonds become CTD, especially given the limited supply of new bonds and the historical preference for older bonds as CTD [5] Group 2: Pharmaceutical Industry - The domestic weight-loss drug innovation sector is advancing, with several companies making significant progress in clinical trials and regulatory approvals [6][7] - Notable developments include the completion of clinical trials by Zhongsheng Pharmaceutical and FDA approvals for drugs from Lianbang Pharmaceutical and Laikai Pharmaceutical, indicating a robust pipeline for weight-loss treatments [6][7] - The year 2025 is projected to be pivotal for the commercialization of competitive domestic weight-loss drugs, with several companies receiving regulatory approvals and entering the market [7][36] Group 3: Technology and Media - Spotify is positioned as a leading global music streaming platform, with a projected revenue growth from €173 billion in 2025 to €230 billion by 2027, driven by its unique business model and strong user base [8][9] - The company has invested heavily in content and technology, enhancing its competitive edge and user experience, with active users reaching 696 million in Q2 2025 [8][9] - Spotify's strategy includes localizing content for emerging markets and leveraging AI to improve user engagement and profitability [10] Group 4: Communication Equipment and Services - The communication industry is experiencing a positive shift, with fund holdings increasing to 3.90% in Q2 2025, indicating renewed investor interest [11][13] - Key players in the AI computing supply chain are expected to benefit from ongoing investments and technological advancements, with significant capital expenditures anticipated from major domestic internet companies [12][13] - The communication sector is recommended for investment, particularly companies closely tied to the AI industry, as they are likely to see substantial growth [12][13]

Group 1 - Source Le Sheng Asset Management conducted research on the listed company Borui Pharmaceutical, focusing on the collaboration with China Resources Sanjiu to expedite the commercialization of the BGM0504 product in China [1] - China Resources Sanjiu is confident in the BGM0504 product and plans to conduct more clinical trials to demonstrate its advantages, indicating a strong partnership [1] - The BGM0504 product is expected to have global competitiveness and plans for international expansion without affecting global rights [1] Group 2 - BGM1812 is characterized by fat reduction without muscle loss and has mild side effects, with ongoing IND applications in China and the US [1] - The collaboration with Hanyu Pharmaceutical is aimed at preparing for future commercialization needs and regulatory market clinical and industrialization [1]

Group 1 - Dan Yi Investment recently conducted research on a listed company, specifically focusing on BoRui Pharmaceutical [1] - BoRui Pharmaceutical is collaborating with China Resources Sanjiu to expedite the commercialization of the BGM0504 product in China, leveraging Sanjiu's hospital access and promotional capabilities [1] - China Resources Sanjiu expresses confidence in the BGM0504 product and plans to conduct more clinical trials to demonstrate its advantages [1] - The BGM0504 product is considered globally competitive, with plans for international expansion that will not affect global rights [1] - The BGM1812 product is characterized by fat reduction without muscle loss and has mild side effects, with ongoing IND applications in China and the U.S. [1] - BoRui Pharmaceutical is preparing for future commercialization needs and regulatory market clinical and industrialization through collaboration with Hanyu Pharmaceutical [1] Group 2 - Dan Yi Investment Management Partnership was established in April 2015 with a registered capital of 10 million [2] - The company has a management record with the China Securities Investment Fund Industry Association, with a registration number of P1015236 [2] - The core executives of the company have over ten years of experience in investment research, having previously worked at prominent institutions such as Huabao Xingye Fund and Guotou Ruijin Fund [2]

Group 1 - The core viewpoint is that Secheng Investment has conducted research on the listed company Borui Pharmaceutical, focusing on the collaboration with China Resources Sanjiu to commercialize the BGM0504 product rapidly in China [1] - Borui Pharmaceutical's BGM0504 product is expected to demonstrate its advantages through more clinical trials, and it possesses global competitiveness with plans for international expansion [1] - The BGM1812 product is characterized by fat reduction without muscle loss and is currently advancing IND applications in both China and the United States [1] Group 2 - Secheng Investment was established in 2007 with a registered capital of 30 million yuan and is a member of the fund industry association, focusing on equity investments and maintaining a "high-quality growth" investment philosophy [2] - The company has received numerous industry awards and has established long-term asset management cooperation with several large financial institutions since its inception [2]

Group 1 - Gao Yi Asset recently conducted research on a listed company, specifically focusing on Bo Rui Pharmaceutical [1] - Bo Rui Pharmaceutical is collaborating with China Resources Sanjiu to expedite the commercialization of the BGM0504 product in China, leveraging China Resources Sanjiu's hospital access and promotional capabilities [1] - China Resources Sanjiu is confident in the BGM0504 product and plans to conduct more clinical trials to demonstrate its advantages [1] - The BGM0504 product is considered globally competitive, with plans for international expansion that will not affect global rights [1] - BGM1812 is characterized by fat reduction without muscle loss and has mild side effects, with ongoing IND applications in China and the U.S. [1] - Collaboration with Hanyu Pharmaceutical is aimed at preparing for future commercialization needs and regulatory market clinical and industrialization [1] Group 2 - Gao Yi Asset Management is a prominent private equity fund management company in China, known for its strong research capabilities and large management scale [2] - The company focuses on capital markets and aims to provide top-notch research support, channel resources, brand endorsement, capital connection, and operational maintenance for outstanding investment managers [2] - The research team consists of over 30 members, including experienced investment managers with a history of strong performance in the market [2] - Gao Yi Asset is registered with the Asset Management Association of China and has its headquarters in Shanghai, with teams located in Shenzhen, Shanghai, and Beijing [2]

Group 1 - The core viewpoint of the news is that Fusheng Asset has conducted research on the listed company Borui Pharmaceutical, focusing on the collaboration with China Resources Sanjiu to commercialize the BGM0504 product in China quickly [1] - Borui Pharmaceutical's BGM0504 product is expected to demonstrate its advantages through more clinical trials, and it has global competitiveness with plans for international expansion [1] - The BGM1812 product is characterized by fat reduction without muscle loss and is currently advancing IND applications in both China and the United States [1] Group 2 - Fusheng Asset Management, established in 2015, is one of the first research-driven private equity fund management companies in China, with a pure equity management scale exceeding 60 billion [2] - The core investment research team at Fusheng Asset has over 16 years of investment experience across mainland China, Hong Kong, and the United States, with fund managers having top-tier public fund investment experience [2] - The company emphasizes sustainable investment and aims to achieve long-term stable returns for investors, having received multiple awards for its performance in the private equity sector [2]

Group 1 - The core viewpoint is that Chengrui Investment has conducted research on the listed company Borui Pharmaceutical, focusing on the collaboration with China Resources Sanjiu to commercialize the BGM0504 product in China [1] - Borui Pharmaceutical's BGM0504 product is expected to demonstrate its advantages through more clinical trials, and it has global competitiveness with plans for international expansion [1] - The BGM1812 product is characterized by fat reduction without muscle loss and is currently advancing IND applications in both China and the US [1] Group 2 - Chengrui Investment, established in May 2010, has a registered capital of 11 million and has been recognized for its stable development in the secondary market and various investment strategies [2] - The company has a professional research team of 33 members, with backgrounds from prestigious universities, and has received multiple industry awards for its performance [2] - Chengrui Investment has diversified its client base, which includes banks, private banks, securities firms, insurance companies, trusts, and various institutional investors [2]

Group 1: Government Bond Tax Policy Impact - The Ministry of Finance and the State Taxation Administration announced that from August 8, 2025, interest income from newly issued government bonds, local government bonds, and financial bonds will be subject to value-added tax, reversing the previous tax exemption [2][3] - The market is particularly concerned about whether this change will lead to cross-period arbitrage opportunities or short squeeze phenomena in government bond futures, which hinges on whether there will be a switch in the cheapest-to-deliver (CTD) bonds [2][4] Group 2: CTD Bond Switching Dynamics - Generally, new bonds find it difficult to replace old bonds as CTD bonds unless they offer a yield premium of over 15 basis points, which is challenging to achieve in practice [3] - However, exceptions exist for T contracts and TS contracts, where new bonds can more easily become CTD bonds due to their shorter duration and lower required discount [3][4] Group 3: Cross-Period Arbitrage Opportunities - The potential for cross-period arbitrage in government bond futures depends on whether the CTD bonds for near and far month contracts switch, which could lead to price discrepancies [4] - The upcoming issuance of new 2-year and 7-year bonds on September 12 may trigger CTD bond switches, creating arbitrage opportunities between TS2512-TS2603 and T2512-T2603 [4] Group 4: Short Squeeze Potential - There is a possibility of a short squeeze in government bond futures if new bonds become CTD bonds, especially given the limited supply of new bonds initially [5] - The market's lack of experience with new bonds as CTD bonds could exacerbate the short squeeze pressure, particularly for contracts like T and TS2603, which are associated with new 7-year and 2-year bonds [5] Group 5: Domestic Weight Loss Drug Innovations - Domestic pharmaceutical companies are making significant progress in the development of innovative weight loss drugs, with several companies completing key clinical trials and receiving regulatory approvals [9][10] - The year 2025 is anticipated to be a pivotal year for the commercialization of competitive domestic weight loss drugs, with notable advancements in clinical data and market readiness [10][11] Group 6: Fund Holdings in Communication Sector - The fund holdings in the communication sector have shown a positive trend, with a 1.31 percentage point increase in the market value share, indicating a recovery in investor confidence [15] - The AI computing power supply chain remains a focal point for investment, with significant capital expenditures expected from major domestic internet companies [14][15]